Results 1 to 10 of about 680,911 (114)

Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions

World Psychiatry, 2023
Treatment‐resistant depression (TRD) is common and associated with multiple serious public health implications. A consensus definition of TRD with demonstrated predictive utility in terms of clinical decision‐making and health outcomes does not currently
Richard Shelton, Josefina Ly-Uson
exaly   +2 more sources

Transformative Therapies for Depression: Postpartum Depression, Major Depressive Disorder, and Treatment-Resistant Depression

Annual Review of Medicine
Depressive disorders present an enormous global public health burden. A notable treatment gap exists between the prevalence of depression and our ability to provide rapid-acting, effective treatment that achieves remission.

exaly   +2 more sources

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Psychopharmacology, 2017
Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment ...
David Nutt, M Kaelen, A Feilding
exaly   +2 more sources

Potential efficacy of dopaminergic antidepressants in treatment resistant anergic-anhedonic depression results of the chronic anergic-anhedonic depression open trial – CADOT

Frontiers in Psychiatry, 2023
IntroductionAmong treatment-resistant depression (TRD), we identified anergic-anhedonic clinical presentations (TRAD) as putatively responsive to pro-dopaminergic strategies.
Ludovic Christophe Dormegny-Jeanjean, Ludovic Christophe Dormegny-Jeanjean, Ludovic Christophe Dormegny-Jeanjean, Clément de Billy, Clément de Billy, Clément de Billy, Olivier Mainberger, Olivier Mainberger, Olivier Mainberger, Sébastien Weibel, Sébastien Weibel, Sébastien Weibel, Benoit Schorr, Benoit Schorr, Benoit Schorr, Alexandre Obrecht, Alexandre Obrecht, Lionel Landré, Fabrice Berna, Fabrice Berna, Jean-Baptiste Causin, Jean-Baptiste Causin, Jean-Baptiste Causin, Frederic Blanc, Frederic Blanc, Vlad Danila, Vlad Danila, Mihaela Tomsa, Mihaela Tomsa, Geraldine Pfleger, Geraldine Pfleger, Camille Meyer, Camille Meyer, Camille Meyer, Ilia Humbert, Ilia Humbert, Ilia Humbert, Hervé Javelot, Hervé Javelot, Guillaume Meyer, Guillaume Meyer, Gilles Bertschy, Gilles Bertschy, Gilles Bertschy, Jack Rene Foucher, Jack Rene Foucher, Jack Rene Foucher, Jack Rene Foucher   +47 more
doaj   +1 more source

Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation

American Journal of Psychiatry, 2021
Replicated international studies have underscored the human and societal costs associated with major depressive disorder. Despite the proven efficacy of monoamine-based antidepressants in major depression, the majority of treated individuals fail to ...
R. McIntyre, J. Rosenblat, C. Nemeroff, G. Sanacora, J. Murrough, M. Berk, E. Brietzke, S. Dodd, P. Gorwood, R. Ho, D. Iosifescu, Carlos A. López Jaramillo, S. Kasper, Kevin Kratiuk, J. G. Lee, Yena Lee, L. Lui, R. Mansur, G. Papakostas, M. Subramaniapillai, M. Thase, E. Vieta, A. Young, C. Zarate, S. Stahl   +24 more
semanticscholar   +1 more source

Treatment-resistant depression reconsidered

SSM - Mental Health, 2022
The term treatment-resistant depression (TRD) has been the focus of hundreds of studies and clinical trials, though it is not a diagnosable mental health condition according to current clinical standards.
Hans S. Schroder, Elissa H. Patterson, Laura Hirshbein   +2 more
doaj   +1 more source

Editorial: Treatment resistant depression (TRD): epidemiology, clinic, burden and treatment

Frontiers in Psychiatry
Andrea Fiorillo, Koen Demyttenaere, Vassilis Martiadis, Giovanni Martinotti   +3 more
doaj   +2 more sources

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression

European Psychiatry, 2022
Introduction The compassionate use of intranasal esketamine is approved in Spain for treatment-resistant depression (TRD). Objectives The objective of the study is to assess the clinical stability in the medium-term follow-up of patients with TRD after
D. Hernandez Huerta, A. De Santiago Diaz, C. Rodriguez Gomez-Carreño, M.A. Abril Garcia, F. Toledo Romero, A. Guerrero Morcillo, C.J. Martinez Pastor, M. Vega Piñero   +7 more
doaj   +1 more source

Clinical efficacy and tolerability of Esketamine: a case series

European Psychiatry, 2022
Introduction Esketamine is a novel antidepressant approved by the FDA in 2019 in the form of an intranasal spray, recommended for Treatment-Resistant Depression (TRD).
C. Passani, N. Ragone, C.M. Congedo, B. Barbini, R. Zanardi, M.C. Cavallini, C. Colombo   +6 more
doaj   +1 more source

Psilocybin's Emerging Role in Combating Depressive Disorder

Journal of Education, Health and Sport, 2023
        In this review paper, we delve into the potential applicability of psilocybin - a naturally synthesized psychedelic substance found within select species of fungi, as a prospective avenue for depression treatment.
Anna Jaremek, Joanna Kępa, Norbert Kandefer, Michał Wyszkowski, Aleksandra Grabarczyk, Anna Pawlak, Sylwia Grad, Małgorzata Gregorek, Paweł Gregorek   +8 more
doaj   +1 more source